您的位置：山东大学 -> 科技期刊社 -> 《山东大学学报（医学版）》

山东大学学报（医学版） ›› 2014, Vol. 52 ›› Issue (10): 77-80,95.doi: 10.6040/j.issn.1671-7554.0.2014.360

• 临床医学 • 上一篇    下一篇

多囊卵巢综合征患者卵泡液中GDF9和BMP15的表达及意义

哈灵侠1,2, 李向红1,2   

  1. 1. 宁夏医科大学总医院生殖医学中心, 宁夏 银川 750004;
    2. 宁夏回族自治区生殖与遗传重点实验室 生育力保持省部共建教育部重点实验室, 宁夏 银川 750004
  • 收稿日期:2014-06-01 修回日期:2014-09-12 出版日期:2014-10-10 发布日期:2014-10-10
  • 通讯作者: 哈灵侠。E-mail：hlxny@163.com E-mail:hlxny@163.com
  • 基金资助:
    宁夏回族自治区自然科学基金（NZ1231）

Expression and significance of GDF9 and BMP15 in follicular fluid of women with polycysticovary syndrome

HA Lingxia1,2, LI Xianghong1,2   

  1. 1. Center for Reproductive Medicine, General Hospital of Ningxia Medical University, Yinchuan 750004, Ningxia, China;
    2. Key Laboratory of Reproduction and Genetics, Key Laboratory of Fertility Preservation and Maintenance, Ningxia Medical University, Ministry of Education in Ningxia, Yinchuan 750004, Ningxia, China
  • Received:2014-06-01 Revised:2014-09-12 Online:2014-10-10 Published:2014-10-10

PDF (PC)

237

摘要： 目的 探讨体外受精-胚胎移植（IVF-ET）周期多囊卵巢综合征（PCOS）患者卵泡液中卵源性因子-生长分化因子9（GDF9）和骨形态发生蛋白15（BMP15）的表达及对IVF结局的影响。方法 收集60例PCOS患者（PCOS组）及60例卵巢功能正常妇女（对照组），分别记录患者一般情况、获卵数、成熟卵子数、正常受精卵数、卵裂数、优质胚胎数和临床妊娠率。Western blotting 检测所有对象卵泡液中GDF9和BMP15蛋白的表达量。根据阴道B超是否见到孕囊将PCOS患者进一步分为妊娠组和非妊娠组，分析两组卵泡液中GDF9和BMP15蛋白的表达情况。结果 ①PCOS组与对照组比较，获卵数分别为（18.76±8.51）个和（11.23±4.29）个，差异有统计学意义（P<0.05）；成熟卵子率、受精率、卵裂率、优质胚胎率和临床妊娠率差异无统计学意义（P>0.05）。②PCOS组卵泡液中GDF9和BMP15的表达量分别为0.85±0.27和1.29±0.48，对照组卵泡液中GDF9和BMP15的表达量分别为1.33±0.24和1.94±0.57，两组比较差异均有统计学意义（P<0.05）。③PCOS患者妊娠组GDF9和BMP15的表达量分别为1.01±0.31和1.50±0.41，非妊娠组GDF9和BMP15的表达量分别为0.71±0.21和1.09±0.46，两组比较差异均有统计学意义（P<0.05）。结论 经促排卵刺激的PCOS 患者卵泡液中GDF9、BMP15蛋白表达低于正常对照组，其表达水平的低下可能影响卵母细胞质量和胚胎发育潜能；妊娠组卵泡液GDF9、BMP15蛋白表达高于未妊娠组，提示卵源性因子GDF9、BMP15高表达可能与良好的妊娠结局相关。

关键词: 多囊卵巢综合征, 骨形态发生蛋白15, 生长分化因子9, 体外受精-胚胎移植

Abstract: Objective To investigate the expression of growth differentiation factor9 (GDF9) and bone morphogenetic protein15 (BMP15) in follicular fluid of polycystic ovarian syndrome (PCOS) patients and the effects on the outcome of in vitro fertilization and embryo transfer (IVF-ET). Methods A total of 60 PCOS patients (PCOS group) and 60 women with normal ovarian function (control group) were collected. The general information, the numbers of oocytes, mature oocytes, fertilized oocytes, cleavage, high quality embryos, and the rate of clinical pregnancy were recorded. Western blotting was used to detect the expressions of GDF9 and BMP15 in the follicular fluid of all subjects. The PCOS group was further divided into pregnant and non-pregnant subgroups according to the presence of a gestational sac on ultrasound. The expressions of GDF9 and BMP15 were analyzed. Results ① The number of oocytes was 18.76±8.51 and 11.23±4.29 in the PCOS group and control group, with significant difference (P<0.05). The number ofmature eggs, fertilization rate, cleavage rate, good quality embryo and the clinical pregnancy rate between the two groups had no significant differences (P>0.05). ② The expressions of GDF9 and BMP15 were 0.85±0.27 and 1.29±0.48 in the PCOS group, and 1.33±0.24 and 1.94±0.57 in the control group, with significant difference (P<0.05). ③ The expressions of GDF9 and BMP15 were 1.01 ± 0.31 and 1.50 ± 0.41 in the pregnant subgroup, and 0.71±0.21 and 1.09±0.46 in the non-pregnant subgroup, with significant difference (P<0.05). Conclusion The expressions of GDF9 and BMP15 in follicular fluid in the PCOS group are lower than those of the control group, suggesting that the low expression may affect oocyte quality and embryo development potential. The expressions of GDF9 and BMP15 in follicular fluid of the pregnant subgroup are higher than those of the non-pregnant subgroup, suggesting that the high expression may be associated with a good pregnancy outcome.

Key words: Polycystic ovary syndrome, In vitro fertilization and embryo transfer, Growth differentiation factor 9, Bone morphogenetic protein 15

中图分类号: 

  • R711.6
[1] March W A, Moore V M, Willson K J, et al. The prevalence of polycystic ovary syndrome in acommunity sample assessed under contrasting diagnostic criteria[J]. Hum Reprod, 2010, 25(2):544-551.
[2] Gilchrist R B, Lane M, Thompson J G. Oocyte-secreted factors:regulators of cumulus cell function and oocyte quality[J]. Hum Reprod Update, 2008, 14(2):159-177.
[3] Otsuka F, McTavish K J, Shimasaki S. Integral role of GDF-9 and BMP-15 in ovarian function[J]. Mol Reprod Dev, 2011, 78(1):9-21.
[4] Van Houten E L, Laven J S, Louwers Y V, et al. Bone morphogenetic proteins and the polycystic ovary syndrome[J]. J Ovarian Res, 2013, 6(1):32. doi:10.1186/1757-2215-6-32.
[5] Wei L N, Liang X Y. Growth Differentiation Factor 9, Bone Morphogenetic Protein 15 and Polycystic Ovary Syndrome[J]. J Int Reprod/Fam Plan, 2011, 30:251-254.
[6] Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome(PCOS)[J]. Hum Reprod, 2004, 19(1):41-47.
[7] Okohue J E, Onuh S O, Ikimalo J I. Comparison of IVF/ICSI outcome in patients with polycystic ovarian syndrome or tubal factor infertility[J]. Niger J Clin Pract, 2013, 16(2):207-210.
[8] Dumesic D A, Abbott D H. Implications of polycystic ovary syndrome on oocyte development[J]. Semin Reprod Med, 2008, 11(1):53-61.
[9] Qiao J, Feng H L. Extra-and intra-ovarian factors in polycystic ovary syndrome:impact on oocyte maturation and embryo developmental competence[J]. Hum Reprod Update, 2011, 17(1):17-33.
[10] Han A R, Kim H O, Cha S W, et al. Adverse pregnancy outcomes with assisted reproductive technology in non-obese women with polycystic ovary syndrome:a case control study[J]. Clin Exp Reprod Med, 2011, 38(2):103-108.
[11] Welt C K, Gudmundsson J A, Arason G, et al. Characterizing discrete subsets of polycystic ovary syndrome as defined by the Rotterdam criteria:the impact of weight on phenotype and metabolic features[J]. J Clin Endocrinol Metab, 2006, 91 (12):4842-4848.
[12] Otsuka F, McTavish K J, Shimasaki S. Integral role of GDF-9 and BMP-15 in ovarian function[J]. Mol Reprod Dev, 2011, 78(1):9-21.
[13] Paulini F, Melo E O. The role of oocyte-secreted factors GDF9 and BMP15 in follicular development and oogenesis[J]. Reprod Domest Anim, 2011, 46(2):354-361.
[14] Wei L N, Liang X Y, Fang C, et al. Abnormal expression of growth differentiation factor 9 and bone morphogenetic protein 15 in stimulated oocytes during maturation from women with polycystic ovary syndrome[J]. Fertil Steril, 2011, 96(2):464-468.
[15] Zhao S Y, Qiao J, Chen Y J, et al. Expression of growth differentiation factor-9 and bone morphogenetic protein-15 in oocytes and cumulus granulosa cells of patients with polycystic ovary syndrome[J]. Fertil Steril, 2010, 94(1):261-267.
[16] Wei L N, Li L L, Fang C, et al. Inhibitory effects of controlled ovarian stimulation on the expression of GDF9 and BMP15 in oocytes from women with PCOS[J]. J Assist Reprod Genet, 2013, 30(10):1313-1318.
[17] Yeo C X, Gilchrist R B, Lane M. Disruption of bidirectional oocyte-cumulus paracrine signaling during in vitro maturation reduces subsequent mouse oocyte developmental competence[J]. Biol Reprod, 2009, 80(5):1072-1080.
[18] Su J, Wang Y, Zhang L, et al. Oocyte-secreted factors in oocyte maturation media enhance subsequent development of bovine cloned embryos[J]. Mol Reprod Dev, 2014, 81(4):341-349.
[19] Wu Y T, Tang L, Cai J, et al. High bone morphogenetic protein-15 level in follicular fluid is associated with high quality oocyte and subsequent embryonic development[J]. Hum Reprod, 2007, 22(6):1526-1531.
[20] Zhang Y M, Lin X N, Zhou F, et al. Influence of Bone Morphogenetic Protein(BMP)-15 on the IVF Outcomes of Endometriosis-A Clinical Trail and Experimental Research[J]. Journal of Reproduction & Contraception, 2012, 32(11):739-743.
[1] 丁祥云,于清梅,张文芳,庄园,郝晶. 胰岛素样生长因子II在84例多囊卵巢综合征患者颗粒细胞中的表达和促排卵结局的相关性[J]. 山东大学学报 (医学版), 2020, 1(7): 60-66.
[2] 张素萍,王泽,周亚丽, 李敬,路西兰,柏宏伟,石玉华. 来曲唑治疗不同体质量指数多囊卵巢综合征患者的临床效果[J]. 山东大学学报（医学版）, 2017, 55(5): 81-85.
[3] 杨冬梓,麦卓瑶. 高龄多囊卵巢综合征患者的卵巢储备特点及其助孕结局[J]. 山东大学学报（医学版）, 2017, 55(1): 26-32.
[4] 贾月月,刘洪彬,李婧博,李敬,张江涛, 孙梅,石玉华. 多囊卵巢综合征患者颗粒细胞microRNA-200b的表达及影响[J]. 山东大学学报（医学版）, 2017, 55(1): 63-68.
[5] 李婧博,刘洪彬,贾月月,王泽,孙梅,石玉华. microRNA-183在PCOS胰岛素抵抗中的表达及其临床意义[J]. 山东大学学报（医学版）, 2017, 55(1): 69-74.
[6] 张琳,李敬,王泽,张江涛,马增香,石玉华. 多囊卵巢综合征患者促甲状腺激素对血糖、血脂的影响[J]. 山东大学学报（医学版）, 2017, 55(1): 80-84.
[7] 王玮, 常康, 李晓冬, 郝桂敏. 胰岛素增敏剂对PCOS大鼠子宫内膜胰岛素受体底物表达的影响[J]. 山东大学学报（医学版）, 2014, 52(12): 24-29.
[8] 哈灵侠1,2, 石玉华1, 赵君利2, 陈子江1. 宁夏地区多囊卵巢综合征患者不同雄激素状态脂代谢特点的比较性分析[J]. 山东大学学报(医学版), 2013, 51(9): 88-91.
[9] 鹿群，沈浣，王丛，郑兴邦，陈曦，梁蓉,魏丽惠. 脱氢表雄酮对卵巢反应不良患者体外受精-胚胎移植的影响[J]. 山东大学学报(医学版), 2013, 51(2): 84-.
[10] 杨柳，张磊，李春辉，王志萍. 胆固醇侧链裂解酶基因微卫星多态性与多囊卵巢综合征发病风险的关联[J]. 山东大学学报(医学版), 2013, 51(10): 85-89.
[11] 王玮1,滑天2,曹金凤1,崔娜1,杨爱敏1,姜蕾1,郝桂敏1. 来曲唑在多囊卵巢综合征促排卵中的应用[J]. 山东大学学报(医学版), 2013, 51(06): 25-28.
[12] 郑荣华，石玉华，盛燕，高芹，高选，陈子江. 多囊卵巢综合征患者白细胞计数的变化特点[J]. 山东大学学报(医学版), 2012, 50(7): 78-80.
[13] 王月恒1，邢毅2，王玖玲1，代军3，李淑玲1. 多囊卵巢综合征患者血清内脂素及TNF-α的水平变化及其意义[J]. 山东大学学报(医学版), 2012, 50(2): 94-.
[14] 王玖玲,朱敏华,李淑玲,李辉 . 益肾活血法治疗未破裂卵泡黄素化综合征的临床研究[J]. 山东大学学报(医学版), 2008, 46(2): 204-206.
[15] 陈子江. 雄激素对卵母细胞生长分化因子[J]. 山东大学学报(医学版), 2006, 44(6): 549-552.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
版权所有 © 2018 《山东大学学报(医学版)》编辑部　
地址:山东大学科技期刊社（济南市历城区山大南路27号山东大学中心校区明德楼B座721室） 电话: 0531-88366918 E-mail: xbyxb@sdu.edu.cn
本系统由北京玛格泰克科技发展有限公司设计开发